LivingGLP1
Study S002207

The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity

ClinicalTrials.gov record

Registration

Registration
NCT06331286
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Status
UNKNOWN
Enrollment
60
Start
2023-09-01
Primary completion
2024-12-31
Lead sponsor
First Affiliated Hospital of Zhejiang University
Conditions
Bipolar Disorder; Obesity; Cognition
Interventions
DRUG:dulaglutide injection
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • weight [Baseline, the end of Week 12 and the end of Week 24]
  • Concentration of blood glucose in blood [Baseline, the end of Week 12 and the end of Week 24]
  • Concentration of total cholesterol in blood [Baseline, the end of Week 12 and the end of Week 24]
  • Concentration of high density lipoprotein in blood [Baseline, the end of Week 12 and the end of Week 24]
  • Concentration of low density lipoprotein in blood [Baseline, the end of Week 12 and the end of Week 24]
  • Concentration of triglyceride in blood [Baseline, the end of Week 12 and the end of Week 24]
  • CBCT test results [Baseline, the end of Week 12 and the end of Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.